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ABSTRACT
Magnetotactic bacteria (MTB) are aquatic microorganisms that are able to biomineralize membrane-enclosed magnetic nanoparticles
called magnetosomes. Inside the MTB, magnetosomes are arranged in a chain that allows MTB to align and navigate along the Earth’s
magnetic field. When isolated from the MTB, magnetosomes display a number of potential applications for targeted cancer therapies,
such as magnetic hyperthermia, localized drug delivery, or tumor monitoring. The characteristics and properties of magnetosomes for
these applications exceed in several aspects those of synthetic magnetic nanoparticles. Likewise, the whole MTB can also be considered
as promising agents for cancer treatment, taking advantage of their self-propulsion capability provided by their flagella and the guid-
ance capabilities ensured by their magnetosome chain. Indeed, MTB are envisaged as nanobiots that can be guided and manipulated by
external magnetic fields and are naturally attracted toward hypoxic areas, such as the tumor regions, while retaining the therapeutic and
imaging capacities of the isolated magnetosomes. Moreover, unlike most of the bacteria currently tested in clinical trials for cancer
therapy, MTB are not pathogenic but could be engineered to deliver and/or express specific cytotoxic molecules. In this article, we will
review the progress and perspectives of this emerging research field and will discuss the main challenges to overcome before the use of
MTB can be successfully applied in the clinic.
© 2020 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license
(http://creativecommons.org/licenses/by/4.0/). https://doi.org/10.1063/5.0018036
INTRODUCTION
Cancer is one of the most common causes of death worldwide.
According to the Global Cancer Observatory,1 only in 2018,
around 18.1 × 106 new cases were reported, with a mortality rate
higher than 50%. These statistics reflect the need of finding novel
strategies and more effective cancer treatments that substitute or
complement the current ones, namely, surgery, chemotherapy,
radiotherapy, and immunotherapy. These new strategies should
overcome the known limitations that are inherent to standard treat-
ments, such as unspecific targeting, shallow penetration of electro-
magnetic fields, heterogeneous distribution in the tumor area, and
non-selective cytotoxicity. The visionary speech delivered by
Richard Feynman in 1959,2 which anticipated numerous technolog-
ical advances that are ubiquitous nowadays, also introduced the
idea of using small machines as robotic surgeons. These should be
capable of navigating through the vascular system of the body, spe-
cifically, finding the damaged cells or organs and performing
locally the therapeutic action. Aiming to materialize what would be
an extraordinary therapeutic tool, different kinds of systems actuat-
ing as nanorobots have been investigated in laboratories across the
world.3 A significant number of them are based on biological enti-
ties such as bacteria and viruses4–6 and many others on inorganic
magnetic nanoparticles (MNPs).7,8
MNPs engineered for biomedical applications are, in the sim-
plest case, composed of a single core magnetic nanoparticle, usually
an iron oxide, surrounded by a biocompatible shell. The diameter
of the nanoparticles is tuned in the range between 5 and 50 nm, a
size that is suitable for the interaction with biological entities and
enables their penetration into cells. In the last decades, much of the
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work has been focused on magnetite (Fe3O4) and maghemite
(γ-Fe2O3), due to their good biocompatibility
9 and their relatively
high magnetic susceptibility and saturation magnetization, resulting
in a high response to external magnetic fields. In addition, they are
currently the only FDA (US Food and Drug Administration) and
EMA (European Medicines Agency) approved magnetic materials
for biomedical treatment.
In this sense, a great effort has been carried out to design
MNPs for specific applications addressing cancer diseases, such
as magnetic hyperthermia, targeted drug delivery, and detection
of cancer cells.7,10,11 In magnetic hyperthermia therapy, MNPs
are injected into the tumor and heated by an external alternating
magnetic field (AMF). Under the AMF, the magnetic response of
the MNPs describes a hysteresis loop, whose area is proportional
to the dissipated energy, producing an elevation of the tempera-
ture in the tumor. A local increase in temperature, around 4–7 °C,
drives cancer cells to apoptosis without affecting the healthy ones.
The use of MNPs in cancer therapy through magnetic hyperther-
mia has been authorized in Europe since 2011, as a co-adjuvant
therapy with conventional radio- and chemotherapies for the
treatment of brain tumors. In 2014, the FDA also approved this
procedure for the treatment of glioblastoma and prostate cancer.
Currently, clinical trials are being carried out by MagForce AG®12
on patients with brain, pancreatic, prostate, breast, and esopha-
geal cancer (see Table I). Alternatively, MNPs are also investi-
gated for targeted drug delivery purposes. The main goal is to
properly functionalize the surface of the nanoparticle with a spe-
cific drug and, through the application of an external magnetic
field gradient, to transport the MNPs toward the tumor tissue.13
Even though a large number of in vivo and in vitro studies have
been performed, there are no ongoing clinical trials so far. MNPs
are also used for tumor localization and imaging. A recent
example of the success of MNPs for tumor localization is the
application developed by Endomag®,14 where a combination of
MNPs (Table I) and a high resolution sensor (Sentimag) is used
to detect and follow the evolution of breast cancer. MNPs for
imaging are employed in the well-established application of
Magnetic Resonance Imaging (MRI) as contrast enhancement
agents, for example, in liver visualization.15
Unfortunately, there are several intrinsic limitations associated
to the use of MNPs as nanorobots. These include their limited pen-
etration through biological barriers, poor reaching and targeting
capacity, and uneven distribution in the tumor tissue. In order to
bypass these and other difficulties, different alternatives have been
proposed in the last few years. Among them, the idea of using bio-
logical entities such as viruses and bacteria to interact with tumors
has been gaining momentum.
Bacteria have a long history in cancer therapy. Already in
1890, Coley16 discovered that some cancer patients recovered after
suffering bacterial infections that destroyed the tumors. Over the
past century, many genera of bacteria have been investigated as
anticancer agents.6 The effectiveness of bacteria against cancer
relies upon their ability to selectively infect and kill the cancer cells
in situ. Motility is one of the key features of bacterial therapy, since
bacteria can actively swim and penetrate deep into the tumor
tissue. It happens that tumors display irregular and chaotic vascula-
ture, leading to areas with low oxygen concentration and nutrient
limitation.17 Such hypoxic regions are a perfect niche for anaerobic
and microaerophilic bacteria to perform selective colonization. The
mechanism behind this bacterial therapy is still not well under-
stood, but there is evidence indicating that bacteria could perform
direct oncolysis and stimulate the immune system.6 Direct oncoly-
sis is mediated by secreting exotoxins in the tumor area and by
competing for nutrients. In addition, bacterial infections activate
the immune system, which targets not only bacteria but also tumor
cells. Another advantage of bacterial therapy is that the bacteria can
be genetically modified to deliver and/or express specific cytotoxic
agents, increasing their effectiveness. In the last years, the FDA
has allowed several clinical trials with tumor-targeting bacteria,
and these human studies show promising antitumor activities
(see Table II). Despite this, so far the only established standard of
medical care with bacteria is the treatment of superficial bladder
cancer using Bacillus Calmette-Guerin (BCG).18
Patients are treated with either intravenous or intratumoral
administration, with only one dose or dose escalation, depending
on the trial. In the particular case of Mycobacterium and bladder
cancer, patients receive repeated instillations of live bacteria into
the bladder. During systemic administration, bacteria disseminate
either in tumor or in healthy tissues. However, a selective coloniza-
tion of the tumor occurs as a consequence of the immunosuppres-
sive and biochemically special microenvironment.19–22
Unfortunately, up to now, the bacteria tested in clinical trials
cannot be guided or tracked inside the body by using external
devices. It is for this reason that a particular group of bacteria,
namely, magnetotactic bacteria (MTB), stand out as a promising
paradigm of bacterial cancer therapy. This is because, as will be
shown in this work, MTB naturally synthesize MNPs, thereby
merging the guidance, control, and therapeutic capabilities of
MNPs with motility, chemical specificity, and the capacity of being
genetically modified of bacteria.
MAGNETOTACTIC BACTERIA (MTB)
The magnetotactic behavior in bacteria was first observed by
Salvatore Bellini (1963)23 in freshwater samples. He observed bacte-
ria swimming northward persistently and suggested the presence of
TABLE I. Currently approved MNPs for cancer clinical purposes.




Sienna+: Dextran-coated iron oxide
MNPs




MRI imaging of the liverc
aManufactured by Magforce; Classification (Council Directive 93/42/EEC)
as a class III medical device.
bManufactured by Endomagnetics Ltd; Classification (Council Directive 93/
42/EEC) as a class IIa medical device.
cManufactured by Fujifilm RI Pharma; Classification (Council Directive 93/
42/EEC) as a drug.
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an internal magnetic compass responsible for their orientation. More
than 10 years later, Blakemore in 197524 discovered bacteria in
marine sediments swimming along the geomagnetic field lines, and
by using transmission electron microscopy, he observed intracellular
magnetic organelles aligned forming a chain inside the bacteria. R. P.
Blakemore referred to the magnetic organelles as magnetosomes and
classified the bacteria as magnetotactic bacteria, MTB.
MTB are aquatic motile microorganisms ubiquitous in marine
and freshwater environments.25 They can passively align, Fig. 1(a),
and actively swim along the geomagnetic field lines, Fig. 1(b), due
to the presence of one or more chains of magnetosomes positioned
along the longitudinal axis of the cell.26–29 This behavior is known
as magnetotaxis.
MTB are microaerobic/anaerobic microorganisms easily found
in the oxic–anoxic transition zones (OATZs) [Fig. 1(b)] with verti-
cal chemical gradients. MTB have sensory elements that guide
them to the regions with their preferred oxygen concentration, an
ability called aerotaxis. Given these circumstances, magnetotaxis is
a great advantage to search their nutritional requirement.26 The
geomagnetic field lines act as a pathway for searching the optimal
position in the stratified water column, since bacteria aligned in the
Earth’s magnetic field reduce a three-dimensional search to a single
dimension. Moreover, other possible roles of the magnetosomes
have also been suggested, such as acting as detoxifying agents,
capable of scavenging metal ions, or reactive oxygen species.32,33
All MTB described at present show great morphological and
physiological diversities. The described morphotypes include [see
Fig. 2 (top)] curved (a), spirilla (b), cocci (c), rods (d), and even
some colonial bacteria, which form multicellular aggregates.29,34
The only common signature is the capability to swim along mag-
netic field lines, including the Earth’s magnetic field.
Regarding magnetosomes, two structures can be differentiated,
the mineral magnetic core and an organic envelope that consists of
a proteinaceous lipid bilayer membrane.18,27,28 The mineral core
presents high chemical purity, being magnetite, Fe3O4, in most of
the species, though some of them synthesize greigite, Fe3S4. The
composition, morphology, and size of the magnetosomes are char-
acteristics of each species. This fact clearly reflects that the forma-
tion of magnetosomes is driven by a strict genetic control.39 On
the other hand, the morphologies of the crystals can be [see Fig. 2
(bottom)] cube-octahedral (a), elongated prismatic [(b) and (c)],
and bullet- or tooth-shaped [(d) and (e)]. Finally, the size of the
magnetic crystals ranges between 35 and 120 nm. Interestingly, in
this diameter range, MNPs are room-temperature stable single-
magnetic domains,26,29,40–43 see Fig. 1(c). The arrangement of the
magnetosomes in a chain causes the addition of magnetic
moments of every individual magnetosome, turning the cell into a
single magnetic dipole, Fig. 1(d). Obviously, this allows MTB to
behave as compass needles that passively get aligned along mag-
netic field lines.40,44,45
MTB are microorganisms difficult to grow and maintain in the
laboratory,25 and until now, only a few species have been isolated in
axenic culture and deposited in bioresource centers. The first isolated
species from freshwater sediments were Magnetospirillum gryhiswal-
dense MSR-1, Fig. 3(a), and Magnetospirillum magneticum
AMB-1,46,47 Fig. 3(c), in the early 1990s. Both are spirilla and biomi-
neralize cube-octahedral magnetite crystals arranged in a single
chain, Figs. 3(b) and 3(d). These strains are easy to culture, and most
of the recent laboratory work has been carried out with them.
Alternatively, Magnetovibrio blakemorei MV-1,48 Fig. 3(e), is a
marine vibrioid to helicoid morphotype that biosynthesizes elon-
gated magnetite nanoparticles with a crystal morphology described
as truncated hexa-octahedral, Fig. 3(f). Various research groups have
been involved on the mass cultivation of MTB strains.49–54 The
culture media composition and the incubation conditions have been
optimized to increase the growth yield (Ycel) and magnetosome pro-
duction (Ymag) mainly in M. gryphiswaldense MSR-1 and M. mag-
neticum AMB-1. Up to now, the highest values have been reported
for MSR-1, Ycel of 9.16 g/l and Ymag of 356mg/l.
49
Currently, the potential of magnetosomes for biomedical
applications is being widely studied as an alternative to synthetic
MNPs. In fact, magnetosomes are good candidates not only
because of their chemical purity and well-defined morphology and
size in the stable magnetic monodomain range, but also because
they are surrounded by a biocompatible organic envelope that
confers them stability when dispersed in water and facilitates the
attachment of bioactive molecules.55–58 However, in the last years,
seizing the advantage of the self-propulsion capability of MTB pro-
vided by their flagella and the presence of the magnetosome chain,
TABLE II. Bacterial species tested in clinical trials for cancer therapy.a





























Clostridium novyi Solid tumors
Malignant neoplasm of lung
breast, digestive organs,
urinary tract, brain, endocrine





aData obtained from ClinicalTrials.gov database (https://clinicaltrials.gov).
The phase is based on the study’s objective, the number of participants,
and other characteristics. There are five phases: early phase 1 (formerly
listed as phase 0), phase 1, phase 2, phase 3, and phase 4.
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recent works have focused on the use of the whole MTB as a bio-
medical agents. MTB are envisaged as nanobiots that can be
guided and manipulated by external magnetic fields and are natu-
rally attracted toward hypoxic areas such as the tumor regions.
Unlike most of the bacteria currently tested in clinical trials for
cancer therapy (Table II), MTB are not pathogenic but could be
engineered to deliver and/or express specific cytotoxic molecules.
Moreover, the presence of magnetosomes provides the MTB with
biomedical capacities for therapy and imaging attributed to them,
such as the ability to heat up under alternating magnetic fields
for magnetic hyperthermia therapy, avoiding the tedious and low
efficient process needed to isolate the magnetosomes from the
MTB. Figure 4 summarizes the advantages and perspectives of
MTB as potential theranostic agents that will be discussed in the
following sections.
MAGNETOTACTIC BACTERIA AS MAGNETIC
HYPERTHERMIA AGENTS
Since Gilchrist et al.59 demonstrated in 1957 that magnetic
particles could be inductively heated to kill lymphatic metastases,
magnetic hyperthermia has become one of the most promising
emerging techniques for cancer therapy.9,60–62 As mentioned
before, by increasing the temperature of the tumor area up to
42–45 °C, the so-called therapeutic window, cancer cells can even-
tually be led to apoptosis.61 Higher temperatures, >50 °C, would
lead to a more disruptive (and less safe) destruction of the cancer
cells, through thermal ablation.63 In addition, it has been observed
that raising the temperature in the tumor improves the efficiency of
adjuvant therapies, such as chemotherapy and radiotherapy.64
A huge research effort has been focused on maximizing the
heating efficiency of MNPs. Higher heating efficiencies will ensure
lower dosages of MNPs to efficiently increase the temperature in
the tumor area, reaching the desired therapeutic window under a
certain AMF. The efficiency is parametrized by a magnitude
defined as Specific Absorption Rate (SAR)65,66 that can be deter-
mined from the initial slope of the heating curves, ΔT/Δt, recorded












where Cp is the specific heat of the solvent, ms is the mass of the
solvent, and mn is the mass of the MNPs. In addition, since the
heating efficiency of MNPs is proportional to the magnetic energy
losses or the area of the AC hysteresis loop [Fig. 5(b)], the SAR












where Mt is the instantaneous magnetization at time t, Ht is the
amplitude of the oscillating magnetic field of frequency f at time t,
and c is the weight concentration of MNPs in the medium.
FIG. 1. Magnetotaxis behavior. (a)
Transmission electron microscope
image (TEM) of Magnetospirillum gry-
phiswaldense under an external mag-
netic field of 0.5 T. The white arrow
marks the direction of the applied field.
(b) Schematic representation of mag-
netotaxis in the oxic–anoxic transition
zone (OATZ) (Courtesy of Dr. Lourdes
Marcano). Electron holography of (c)
an isolated magnetosome [reproduced
with permission from Thomas et al.,
Acc. Chem. Res. 41, 665 (2008).
Copyright 2008 American Chemical
Society] and (d) a chain of isolated
magnetosomes [reproduced from
Huízar-Félix et al., Appl. Phys. Lett.
108, 063109 (2016). Copyright 2016
AIP Publishing LLC].
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FIG. 2. TEM images of MTB and magnetosomes. Top: Different morphotypes of bacteria: (a) curved, (b) spirilla, (c) cocci, and (d) rod. Adapted with permission from
Bazylinski et al., The Prokaryotes—Prokaryotic Physiology and Biochemistry. Copyright 2013 Springer Nature. Bottom: Crystal morphologies: (a) cube-octahedral, (b) and
(c) elongated prismatic, (d) tooth-shaped, and (e) bullet-shaped. Scale bars, 100 nm. Adapted with permission from Uebe and Schüler, Nat. Rev. Microbiol. 14, 621 (2016).
Copyright 2016 Springer Nature.
FIG. 3. Transmission electron microscopy of (a) M. gryphiswaldense [inset: x-ray absorption near-edge spectroscopy (XANES) spectra of MTB (red) compared to magne-
tite (blue)]; (b) isolated cube-octahedral magnetosomes of (a) (inset: Cryo-electron tomographic image of a single magnetosome); (c) M. magneticum; (d) isolated
cube-octahedral magnetosomes of (c); (e) M. Blakemorei; and (f ) isolated hexo-octahedral magnetosomes of (e).
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Considering the definition of SAR, there are different parameters
that can be tuned to maximize SAR values. On the one hand, there
are external parameters such as the amplitude and frequency of the
magnetic field, and the dosage of MNPs. On the other hand, we have
the intrinsic magnetic properties of MNPs such as magnetic anisot-
ropy and spontaneous magnetization. External parameters are cur-
rently limited by technical, medical, and economical factors.9,60,61 For
example, high-frequency magnetic fields may generate eddy currents
that can be harmful to the patient. Therefore, in clinical trials, the
values of the amplitude, H, and frequency, f, of the AMF are limited
to values in which the effects of the eddy currents are within safety
limits for the patient.67,68
Due to these technical/medical limitations, most of the
research has been focused on improving the intrinsic magnetic
properties of MNPs. Since SAR is proportional to the area of the
hysteresis loop, we look for tuning those parameters that control
FIG. 4. Schematic representation of
the biological mechanisms of MTB that
envisage them as promising nanobiots,
and the perspectives of the use of
MTB as theranostic agents for cancer
treatments.
FIG. 5. (a) Heating curves, ΔTemp vs time, and (b) AC hysteresis loops, M vs H, of M. gryphiswaldense dispersed in water (measured at 300 kHz).
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the area of the loop, fundamentally, the magnetic anisotropy and
the saturation magnetization. Two main strategies have been used
for this purpose, controlling the size and shape of the MNPs69–73
and modifying their composition.74 To this respect, most of the
research studies performed so far have been focused on superpara-
magnetic iron oxide-based nanoparticles (SPIONs).75 The smallest
sizes (<15–20 nm) of SPIONs were, in principle, considered more
adequate for in vivo applications.76 However, SPIONs present a
series of drawbacks for magnetic hyperthermia, especially a ther-
mally unstable magnetic moment at the body temperature. This
can result in subpar magnetic properties and relatively poor
heating efficiency. Therefore, in recent years, different groups have
investigated the use of bigger MNPs (≈20–50 nm). Magnetite
nanoparticles in this size range and, in particular, magnetosomes
from MTB are single magnetic domains that are stable at room
temperature, providing higher hysteresis losses and consequently
higher SAR values.70,77,78 For these larger MNPs, the evolution of
SAR as a function of the magnetic field is explained accurately by a
modified Stoner–Wolhfarth model.58,79,80 The general behavior is
well described in Fig. 6(a) for isolated magnetosomes from M. gry-
phiswaldense: at low magnetic field amplitudes, the SAR value is
small, whereas above a threshold field, the SAR exhibits a rapid
increase, tending to saturate at high magnetic field amplitudes.
The use of magnetosomes for in vitro and in vivo hyper-
thermia treatment has already been tested with very promising
results.56,58,82–84 In a recent work, mice bearing xenografted
MDA-MB-231 breast cancer were treated with chains of magne-
tosomes from M. magneticum AMB-1, under a magnetic field of
H = 200 Oe and f = 198 kHz, leading to the total disappearance
of tumor after 30 days.85 In another work, magnetosomes coated
with poly-L-lysine were administered to mice with glioblastoma.86
The mice were exposed to 27 magnetic hyperthermia sessions,
each lasting 30 min, using a magnetic field of H = 270 Oe and
f = 202 kHz. All of the mice were alive and apparently cured 350
days after the first injection. In addition, it has been shown that
these magnetosomes are capable of maintaining anti-tumor activ-
ity even after suffering high levels of degradation inside the tumor
cells, which makes them ideal candidates for long-term hyperther-
mia treatment.87
However, the delivery method of MNPs, in general, and mag-
netosomes, in particular, to the tumor area is mainly limited nowa-
days to direct intra-tumoral injection, which is only suitable for
well-localized tumors (e.g., prostate), being the procedure inva-
sive.88 Ideally, indirect administration methods, such as intra-
venous or intra-arterial, would be more desirable, but in these
cases, generally fewer MNPs end up reaching the tumor.89,90 To
this respect, MTB present as compelling candidates for magnetic
hyperthermia. Besides their self-propelling capacity and the possi-
bility to guide and track them, the chain configuration of magneto-
somes maximizes their heating efficiency81,91 in comparison to
randomly arranged nanoparticles, and the chain being anchored
inside the bacteria prevents the agglomeration of the magnetosomes
in the tumor, a fact that would decrease their heating efficiency.
One of the first studies on the heating efficiency of the whole
MTB was carried out by Alphandery et al. in 2011.85,92 In that
work, the authors compared the heating efficiency of individual
magnetosomes, magnetosome chains extracted from MTB, and the
whole MTB. The results revealed a much higher heating efficiency
from MTB than from extracted chains and individual magneto-
somes. In 2017, Tabatabaei et al.93 proposed the use of MTB with
attached commercial SPIONs as heat delivering agents to open the
blood–brain barrier for brain tumor treatment. In a more recent
work, Gandia et al.81 studied the heating efficiency of MTB and
compared the results with those obtained by isolated magneto-
somes. A combination of calorimetric and magnetometric methods
was employed to analyze the heating efficiency. The heating effi-
ciency of MTB was measured at AMFs between H = 0–600 Oe and
f = 150–530 kHz under different bacterial configurations: randomly
and parallel aligned (in the viscous medium) and randomly dis-
persed (in water), see Fig. 6(b). Independent of the configuration,
FIG. 6. (a) Experimental SAR normalized by the frequency, SAR/f, measured at f = 150 kHz of isolated magnetosomes of M. gryphiswaldense. The simulated curve for
SAR/f, calculated using the Stoner−Wohlfarth model is also included for comparison. Reproduced with permission from Muela et al., J. Phys. Chem. C 120, 24437 (2016).
Copyright 2013 American Chemical Society. (b) SAR values obtained from hysteresis loops of MTB under different configurations. Measurements were carried out at
f = 300 kHz. Reproduced with permission from Gandia et al., Small 15, 1902626 (2019). Copyright 2019 John Wiley & Sons.
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the therapeutic window could be reached in less than 5 min. With
the increasing magnetic field, the SAR vs H curves described the
typical Stoner–Wohlfarth behavior, with nearly null values for
H < 150 Oe, and a steep increase afterward, tending to saturate for
H > 300 Oe, where the AC loops showed a shape close to the
optimum shape expected for an ideal heating mediator (i.e., rectan-
gular loops with high squareness). Due to the anisotropic nature of
the magnetosome chain, the heating efficiency was maximized
when the bacteria were aligned parallel to the applied magnetic
field. Nevertheless, the heating results obtained with the randomly
dispersed MTB were still better than those typically reported for
MNPs and closer to those obtained in the case of isolated magneto-
somes, see Table III. Therefore, it is clear that the alignment plays
an important role in the heating efficiency of MTB. In addition, the
fact that the loops of the MTB dispersed in water resemble those of
oriented MTB in the viscous medium indicates that physical rota-
tion or Brownian relaxation plays nearly no role in the heating effi-
ciency of MTB.94 This feature suggests that, contrary to what
frequently happens with inorganic MNPs, MTB will still be able to
provide high heating efficiency after penetrating and getting immo-
bilized inside the tumor. Moreover, since the MTB end up being
internalized or attached to the cancer cells, local heating effects can
give rise to deactivation of the cancer cells even if there was no
global rise in the temperature of the medium.
Nowadays, a few in vitro or in vivo hyperthermia tests have been
carried out with MTB in cancer cell lines and tumors in experimental
animals. Gandia et al.81 assayed MTB with human lung A549 carci-
noma cells. After 24 h of contact, SEM and transmission electron
microscope (TEM) images showed the presence of MTB adhered to
or internalized by the cancer cells, Figs. 7(a)–7(c). Cancer cells loaded
with MTB were subjected to an AMF of H = 400Oe and f = 150 kHz
during 45min. An immediate effect was observed after the treatment:
the growth of cancer cells drastically slowed down, and at the end of
the experiment, the number of living cancer cells was three times
lower than the control, Fig. 7(d). In previous studies, in vivo magnetic
hyperthermia was tested with MTB inside mice by Alphandery et al.
in 2011.85 However, no antitumoral activity was observed, which was
attributed to the low temperature increase measured in the tumor
area due to the low bacterial doses employed. Additionally, in parallel,
Chen et al. in 2016,95 studied the use of MTB to kill Staphylococcus
aureus via magnetic hyperthermia. S. aureus is a pathogen that causes
skin and soft tissue infections, and the authors reported that MTB
could effectively kill ∼50% of S. aureus.
MAGNETOTACTIC BACTERIA FOR TARGETED
THERAPIES
A major challenge in cancer therapy is to deliver efficiently the
therapeutic agent to the target site to minimize side effects. In this
line, the use of MNPs stands out as an emerging technology that has
been extensively studied in the last years.11,13 The idea behind it is to
attract the MNPs to the region of interest with the use of magnetic
field gradients. For successful targeting, MNPs will need to counteract
the drag and buoyancy forces of the fluid with a magnetic force that
depends on the field gradient and the magnetic moment of the
MNP,96 so that, for a given field gradient, the force is maximum at
saturation. In the case of SPIONs, saturation only occurs at high
fields, and producing the field strengths and field gradients necessary
to control the movement of the MNPs in deep tissues is challenging,
especially when platforms need to be scaled up to the clinical size.3,11
In this context, MTB present a number of advantages against
MNPs that make them good candidates to implement therapy strat-
egies locally addressed at the tumor site such as targeted drug-
delivery or magnetic hyperthermia. Indeed, MTB have self-
propulsion capabilities provided by their flagella, and the magnetic
moment of the magnetosome chain, made up of the sum of those
of the individual magnetosomes, is high enough to allow the MTB
to passively align along magnetic fields as small as the Earth’s
( 50 μT) in water environments. MTB swim along the magnetic
field lines (magnetotaxis), and therefore, no magnetic field gradi-
ents are necessary to guide them. The navigation of the MTB can
be controlled by torque-based actuation on the magnetosome
chain, which requires less magnetic field strength than the pulling
approaches necessary for MNPs.3 In addition to magnetotaxis, the
navigation direction of the bacteria is also driven by the oxygen
gradients present in the medium (aerotaxis) which favor their pref-
erence for hypoxic regions such as those in the tumors.
However, the possibility of application of remotely guided
bacteria to real clinical cases is still in its very early development.
Preliminary works in this field have shown that M. magneticum
can navigate in capillaries and target mouse tumor xenografts97
and that Magnetococcus marinus carrying drug-loaded nanolipo-
somes [Fig. 8(a)] can be magnetically guided toward hypoxic
regions of colorectal xenografts.98 Here, 55% of the injected MTB
penetrated into the hypoxic regions of the tumor, which was a
large improvement in comparison to the targeting efficiency of
other nanocarriers.
TABLE III. Heating efficiency of isolated magnetosomes and MTB dispersed in water. Considering that, for MTB, the SAR vs magnetic field curve tends to start saturating










(W g−1 kHz−1) Reference
M. gryphiswaldense MSR-1 380 310 0.15 2380 7.7 81
M. magneticum AMB-1 880 108 0.45 864 8.0 92
Isolated magnetosomes of MSR-1 380 310 0.2 1428 4.4 58
Isolated magnetosomes of AMB-1 800 183 1.0 400 2.2 87
Isolated magnetosomes of AMB-1 doped with Co 800 183 1.0 500 2.7 87
Magnetite nanocubes 600 310 1.0 712 2.3 70
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Despite these pioneering in vivo experiments, the majority of
the guidance and motility studies on MTB have been carried out in
controlled environments, mostly in artificially patterned microfluidic
channels, where the movement of the bacteria is analyzed under
optical microscopy99–101 [Fig. 8(b)]. It has been extensively demon-
strated that their trajectories can be readily controlled by an external
magnetic field, being able to navigate against the rather strong oppo-
site flow encountered in the vascular system,99 which is of the order
of 1mm/s.102 There are, however, several other factors that must be
taken into account for understanding the movement of MTB. Once
those are delimited, it will be feasible to put forward a successful
strategy of MTB guidance. First, understanding the interaction
between MTB’s two driving inputs (magnetotaxis and aerotaxis) is
essential for a successful application.103 Second, the specific way in
which the movement is established is determined by the hydrody-
namic interaction between their flagellar propulsion and the charac-
teristics of the flow regime.104,105 Hydrodynamic and magnetic
interactions can also lead to spontaneous self-organization in bacte-
rial clusters.106 This subject is intimately related to the formation and
the collective control of large groups of bacteria or swarms, which
are thought to increase the possibility of success in clinical treat-
ments.107 Besides, the navigation inside the ramified vascular system
presents additional challenges, such as the circumvention of obstacles
encountered at bifurcations,108 the interaction with other elements in
the flow as red blood cells, not to mention the possible interception
of the MTB by macrophages. Finally, as living entities, their use as
nanobiots must consider their individual diversity, that is, the natural
differences in their development influencing, for instance, the size
and maturation of the magnetosome chain, together with other cir-
cumstances that make that not all the specimens move equally, exist-
ing a significant percentage of non-motile MTB.109
CHALLENGES, PERSPECTIVES, AND FUTURE SCOPE
OF MTB AS CANCER THERAPY AGENTS
For the implementation of MTB in cancer therapies, a
number of challenges must be addressed in the near future. Here,
we will focus on three of them.
First, there is the challenge of scaling up the production of
MTB and exploring synthesis tools to tune the magnetic behavior
of MTB through the control of the biomineralization process of the
magnetosomes. Second, MTB’s greatest advantage is their self-
propulsion by flagella and the possibility of controlling their move-
ment by external fields. However, it is necessary to assess the
FIG. 7. Interaction of M. gryphiswaldense MTB with human lung A549 carcinoma cells. (a) SEM image showing MTB (in orange) adhered on the surface of A549 cells.
(b) Fluorescence microscopy image of MTB bearing A549 cells. MTB were labeled with rhodamine (red) and A549 cells were stained with Hoechst (nuclei shown in blue).
(c) TEM image of a cross section of A549 cells showing MTB inside the cell. (d) Time evolution of the number of live A549 cells present in the culture after the MTB
uptake (in green) and after the hyperthermia treatment (in red). A control culture of cells without MTB is also shown (in blue). Reproduced with permission from Gandia
et al., Small 15, 1902626 (2019). Copyright 2019 John Wiley & Sons.
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movement capacity of the bacteria in the bloodstream, together
with the penetration and distribution in the tumor. And third, the
possibility of using the MTB in combination with other therapies
and with diagnostic techniques should be explored.
From a production perspective, although MTB are fastidious
microorganisms to grow in culture, several groups involved in the
mass cultivation of MTB strains report quite high yields.49–54 In
parallel, alternative paths are being put forward to overcome con-
straints associated to the scaling-up of the MTB production. One
of these alternatives comes from introducing and expressing the
genes involved in magnetosome formation into other bacterial
species easy to grow and culture on a large-scale. This procedure
has already been successfully proved in the photosynthetic model
organism Rhodospirillum rubrum.110
Controlling the composition, size, and morphology of the mag-
netosomes during the biomineralization process is an alternative way
to modify the magnetic response of MTB. While these parameters
can be easily tuned in the case of inorganic MNPs, for magneto-
somes this is a challenging task, since these parameters are specific
to the bacterial species and are controlled by a large set of proteins
present in the magnetosome membrane.35–38 A good understanding
of all the proteins involved in the process could be the key to have a
good control over these parameters through genetic engineering,
although this strategy is far from being fully developed. Another
route to modify the composition of magnetosomes consists on
doping the magnetite with 3d transition elements. This is easily
achieved by introducing salts containing 3d elements into the culture
medium (for example, Co, Mn, Ni, Zn, etc.).111–116 The random
FIG. 8. (a) Scanning electron microscopy images of M. marinus (left) and M. marinus with drug-loaded liposomes (diameter, ∼170 nm) attached to the surface of the cell
(right). Reproduced with permission from Felfoul et al., Nat. Nanotechnol. 11, 941 (2016). Copyright 2016 Springer Nature. (b) Trajectories of directed M. magneticum
using an applied magnetic field of 3 mT to swim along the predefined tracks in the flow with a mean velocity of 90 μm s−1 (shear rate of 10 s−1). Predefined tracks are
shown in the inset. Red lines and yellow arrows indicate the swimming trajectories and swimming directions of the bacteria, respectively. Scale bar denotes 10 μm.
Reproduced with permission from Rismani Yazdi et al., Small 14, 1702982 (2017). Copyright 2017 John Wiley & Sons.
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substitution of Fe cations by transition metal dopants in the magne-
tite structure changes the magnetic anisotropy113 and strongly influ-
ences the macroscopic magnetic properties of MTB as can be seen in
Fig. 9. However, in all cases, the amount of dopant element internal-
ized by magnetosomes is less than 5%, and the magnetic changes at
room temperature are still small.
For hyperthermia purposes, each MTB should have as much
magnetite as possible. However, the mass of magnetite per MTB
typically lies around several tens of femtograms. This means that
when the MTB arrive to the tumor area and penetrate inside the
tumor, the MTB should proliferate until the bacterial concentration
reaches 1011 cell/cm3 so that the concentration of magnetite is high
enough for a successful hyperthermia treatment. One way to over-
come this comes from increasing the number of chains and/or the
number of magnetosomes per chain. These parameters are also
genetically controlled and different strategies for the overexpression
of magnetosomes and/or chains have been investigated,117 but we
are far from having a good control on this issue. Another option is
to apply chemical nanoengineering by attaching inorganic MNPs
onto the surface of these MTB.93 This is a very attractive objective
for the future, although it should be explored whether these MNPs
attached to the surface of the MTB affect the remote control and
navigation of MTB inside the human body.
From the perspectives of targeting efficiency and
distribution in the tumor area
MTBs have numerous advantages: self-propelled by flagella,
magnetotaxis that allows MTB to be guided by a given path deter-
mined by an external magnetic field, aerotaxis based on MTB’s
preference to migrate to environments of low oxygen concentra-
tion, and the growth and proliferation of the MTB in sites of low
oxygen concentration, such as those present in tumors.98
A future challenge is to ensure that MTB can efficiently move
in physiological environments.118 Blood flow within human capil-
laries can reach speeds of around 1mm/s, definitely larger than the
typical ones of MTB (up to 0.3 mm/s). Fortunately, in the tumor
environment, blood flow tends to decrease due to the interstitial
fluid pressure, favoring an efficient navigation.119,120
Finally, it is important that these MTB become eventually
degraded and excreted from the body. MTB internalized by cancer
cells have been found to be compartmentalized inside lysosomes
and quickly degraded, leaving behind the magnetosome chain.81
Magnetosomes also degrade slowly over several days, maintaining
persistent hyperthermal properties during this process.57,83 This
slow degradation of the magnetosome chain would allow repeating
the magnetic hyperthermia treatment for several days avoiding the
injection of additional doses of MTB. On the other hand, the deg-
radation of magnetosomes ensures that they are eventually elimi-
nated from the human body.
Perspectives as a combined theranostic agent
It is obvious that magnetic hyperthermia has attracted most of
the attention in the last few years due to the large capacity of mag-
netic fields to penetrate inside the human body. However, there are
other alternatives for increasing localized heat through nanoparti-
cles. In particular, photothermal therapy is based on the use of
laser energy transfer to remotely heat up the nanoparticles.121 The
photothermal therapy has received increasing attention in the last
years, despite the concerns with laser safety and optical penetration
limit. Generally, this treatment requires a lower concentration of
nanoparticles and gives rise to higher heating efficiencies than the
ones achieved with magnetic hyperthermia.121 Although most of
the work in this area had been based on plasmonic gold and silver
nanoparticles, recently different groups have revealed that iron
oxide nanoparticles can also work as photothermal agents.122 In
this line, magnetosomes have shown good results in in vivo cancer
treatment through photothermia, with much higher cancer killing
efficiency than the one solely reached with magnetic hyperther-
mia.56 This has been attributed to the agglomeration of magneto-
somes inside cancer cells, which does not affect their photothermal
efficiency but may lower the magnetic hyperthermia. Considering
these results, similar studies on the photothermal response of the
whole MTB should be carried out. Likewise, a promising strategy
would be to combine both magnetic hyperthermia and photother-
mal therapies of MTB to maximize the heating efficiency.
MTB based therapies such as magnetic hyperthermia and tar-
geted drug delivery could be also combined with diagnostic tech-
niques such as Magnetic Resonance Imaging (MRI) or Magnetic
Particle Imaging (MPI). Regarding MRI, isolated magnetosomes
have been demonstrated to show an outstanding MRI contrasting
performance due to their high magnetic moment and easy func-
tionalization, which envisages them as promising candidates for
molecular imaging.123–125 Recently, MTB have been proposed for
in vivo MRI monitoring of transplanted stem cells.126,127 On the
other hand, MPI is a 3D imaging technique that allows tracking
and quantifying MNPs inside the body with high spatial and tem-
poral resolution.128,129 MPI is based on the non-linear magnetiza-
tion response of MNPs. Recent works have already studied the
potential of magnetosomes isolated from M. gryphiswaldense as
MPI tracers.130 Both the MRI and MPI platforms have been put
forward for the combined tracking and guidance of nanorobotic
magnetic agents.3
Finally, the fine implications of magnetism in the understand-
ing of the magnetic and motility behavior of MTB is yet to be
nailed in the next future. The latter will form the skeleton on
which an efficient body of bio-applications should be built.
FIG. 9. Low temperature (T = 30 K) hysteresis loops of MTB with undoped mag-
netosomes (black dots) compared to MTB with: left: Co-doped (red dots); right:
Mn-doped (blue dots) magnetosomes. Lines are guides for the eye. In both
cases, the saturation magnetization is already reached for H = 2.5 kOe, but the
shape of the loop is remarkably different with an evolution from hard (Co-doped)
to soft (Mn-doped) magnetic behavior.
Journal of
Applied Physics PERSPECTIVE scitation.org/journal/jap
J. Appl. Phys. 128, 070902 (2020); doi: 10.1063/5.0018036 128, 070902-11
© Author(s) 2020
ACKNOWLEDGMENTS
The Spanish and Basque Governments are acknowledged for
funding under Project Nos. MAT2017-83631-C3-R and IT-1245-19,
respectively.
DATA AVAILABILITY
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
REFERENCES
1Global Cancer Observatory, see https://gco.iarc.fr for information on global
cancer statistics.
2R. P. Feynman, Eng. Sci. 23, 22 (1960).
3S. Martel, Biomicrofluidics 10, 021301 (2016).
4N. S. Forbes, Nat. Rev. Cancer 10, 785 (2010).
5N. S. Forbes, R. S. Coffin, L. Deng, L. Evgin, S. Fiering, M. Giacalone,
C. Gravekamp, J. L. Gulley, H. Gunn, R. M. Hoffman, B. Kaur, K. Liu,
H. K. Lyerly, A. E. Marciscano, E. Moradian, S. Ruppel, D. A. Saltzman,
P. J. Tattersall, S. Thorne, R. G. Vile, H. H. Zhang, S. Zhou, and G. McFadden,
J. Immunother. Cancer 6, 1 (2018).
6S. Zhou, C. Gravekamp, D. Bermudes, and K. Liu, Nat. Rev. Cancer 18, 727
(2018).
7Q. A. Pankhurst, J. Connolly, S. K. Jones, and J. Dobson, J. Phys. D Appl. Phys.
36, R167 (2003).
8N. T. K. Thanh, Clinical Applications of Magnetic Nanoparticles: Design to
Diagnosis Manufacturing to Medicine (CRC Press, 2018).
9C. Blanco-Andujar, F. J. Teran, and D. Ortega, Iron Oxide Nanoparticles for
Biomedical Applications (Elsevier, 2018), p. 197.
10Q. A. Pankhurst, N. K. T. Thanh, S. K. Jones, and J. Dobson, J. Phys. D Appl.
Phys. 42, 224001 (2009).
11J. Mosayebi, M. Kiyasatfar, and S. Laurent, Adv. Healthcare Mater. 6, 1700306
(2017).
12MagForce AG, see https://www.magforce.com for information on magnetic
hyperthermia clinical trials carried out at MagForce company.
13P. S. Patrick, Q. A. Pankhurst, C. Payne, T. L. Kalber, and M. F. Lythgoe,
Design and Applications of Nanoparticles in Biomedical Imaging (Springer,
Cham, 2017), pp. 1–23.
14Endomag, see https://www.endomag.com for information on tumor localiza-
tion technologies developed at Endomag company.
15Y.-X. J. Wang, World J. Gastroenterol. 21, 13400 (2015).
16W. T. Bull and W. B. Coley, J. Am. Med. Assoc. XLIX, 1017 (1907).
17R. K. Jain, J. Clin. Oncol. 31, 2205 (2013).
18A. M. Kamat, T. W. Flaig, H. B. Grossman, B. Konety, D. Lamm,
M. A. O’Donnell, E. Uchio, J. A. Efstathiou, and J. A. Taylor, Nat. Rev. Urol.
12, 225 (2015).
19R. W. Kasinskas and N. S. Forbes, Cancer Res. 67, 3201 (2007).
20L. A. Diaz, I. Cheong, C. A. Foss, X. Zhang, B. A. Peters, N. Agrawal,
C. Bettegowda, B. Karim, G. Liu, K. Khan, X. Huang, M. Kohli, L. H. Dang,
P. Hwang, A. Vogelstein, E. Garrett-Mayer, B. Kobrin, M. Pomper, S. Zhou,
K. W. Kinzler, B. Vogelstein, and D. L. Huso, Toxicol. Sci. 88, 562 (2005).
21J. A. Joyce and D. T. Fearon, Cancer Immunol. Immunother. 348, 74 (2015).
22Y. A. Yu, Q. Zhang, and A. A. Szalay, Biotechnol. Bioeng. 100, 567 (2008).
23S. Bellini, Chin. J. Oceanol. Limnol. 27, 3 (2009).
24R. P. Blakemore, Science 190, 377 (1975).
25C. T. Lefevre and D. A. Bazylinski, Microbiol. Mol. Biol. Rev. 77, 497 (2013).
26D. A. Bazylinski and R. B. Frankel, Nat. Rev. Microbiol. 2, 217 (2004).
27D. Faivre and D. Schuler, Chem. Rev. 108, 4875 (2008).
28D. A. Bazylinski, C. T. Lefèvre, and B. H. Lower, in Nanomicrobiology,
edited by L. L. Barton, D. A. Bazylinski, and H. Xu (Springer, New York,
2014), pp. 39–74.
29D. A. Bazylinski, C. T. Lefevre, and D. Schüler, in The Prokaryotes—
Prokaryotic Physiology and Biochemistry, edited by E. Rosenberg, E. F. DeLong,
S. Lory, E. Stackebrandt, and F. Thompson (Springer, Berlin, 2013), pp. 453–494.
30J. M. Thomas, E. T. Simpson, T. Kasama, and R. E. Dunin-Borkowski, Acc.
Chem. Res. 41, 665 (2008).
31A. M. Huízar-Félix, D. Muñoz, I. Orue, C. Magén, A. Ibarra, J. M. Barandiarán,
A. Muela, and M. L. Fdez-Gubieda, Appl. Phys. Lett. 108, 063109 (2016).
32F. F. Guo, W. Yang, W. Jiang, S. Geng, T. Peng, and J. L. Li, Environ.
Microbiol. 14, 1722 (2012).
33D. Muñoz, L. Marcano, R. Martín-Rodríguez, L. Simonelli, A. Serrano,
A. García-Prieto, M. L. Fdez-Gubieda, and A. Muela, Sci. Rep. 10, 11430 (2020).
34F. Abreu, J. L. Martins, T. Souza Silveira, C. N. Keim, H. G. P. L. de Barros,
F. J. G. Filho, and U. Lins, Int. J. Syst. Evol. Microbiol. 57, 1318 (2007).
35R. Uebe and D. Schüler, Nat. Rev. Microbiol. 14, 621 (2016).
36D. Schüler, FEMS Microbiol. Rev. 32, 654 (2008).
37A. Komeili, Z. Li, D. K. Newman, and G. J. Jensen, Science 311, 242 (2006).
38A. Komeili, H. Vali, T. J. Beveridge, and D. K. Newman, Proc. Natl. Acad. Sci.
U.S.A. 101, 3839 (2004).
39M. L. Fdez-Gubieda, A. Muela, J. Alonso, A. García Prieto, L. Olivi,
J. M. Barandiarán, and R. Fernández-Pacheco, ACS Nano 7, 3297 (2013).
40R. B. Frankel, Annu. Rev. Biophys. Bioeng. 13, 85 (1984).
41B. H. Lower and D. A. Bazylinski, J. Mol. Microbiol. Biotechnol. 23, 63 (2013).
42R. E. Dunin-Borkowski, M. R. McCartney, R. B. Frankel, D. A. Bazylinski,
M. Pósfai, and P. R. Buseck, Science 282, 1868 (1998).
43P. Bender, L. Marcano, I. Orue, D. Alba Venero, D. Honecker, L. Fernández
Barquín, A. Muela, and M. L. Fdez-Gubieda, Nanoscale Adv. 2, 1115 (2020).
44R. B. Frankel and R. P. Blakemore, J. Magn. Magn. Mater. 15–18, 1562 (1980).
45I. Orue, L. Marcano, P. Bender, A. García-Prieto, S. Valencia, M. A. Mawass,
D. Gil-Cartón, D. Alba Venero, D. Honecker, A. García-Arribas, L. Fernández
Barquín, A. Muela, and M. L. Fdez-Gubieda, Nanoscale 10, 7407 (2018).
46T. Matsunaga, T. Sakaguchi, and F. Tadakoro, Appl. Microbiol. Biotechnol. 35,
651 (1991).
47K. H. Schleifer, D. Schüler, S. Spring, M. Weizenegger, R. Amann, W. Ludwig,
and M. Köhler, Syst. Appl. Microbiol. 14, 379 (1991).
48D. A. Bazylinski, T. J. Williams, C. T. Lefèvre, D. Trubitsyn, J. Fang,
T. J. Beveridge, B. M. Moskowitz, B. Ward, S. Schübbe, B. L. Dubbels, and
B. Simpson, Int. J. Syst. Evol. Microbiol. 63, 1824 (2013).
49Y. Zhang, X. Zhang, W. Jiang, Y. Li, and J. Li, Appl. Environ. Microbiol. 77,
5851 (2011).
50A. Fernández-Castané, H. Li, O. R. T. Thomas, and T. W. Overton, New
Biotechnol. 46, 22 (2018).
51J. B. Sun, F. Zhao, T. Tang, W. Jiang, J. S. Tian, Y. Li, and J. L. Li, Appl.
Microbiol. Biotechnol. 79, 389 (2008).
52K. T. Silva, P. E. Leão, F. Abreu, J. A. López, M. L. Gutarra, M. Farina,
D. A. Bazylinski, D. M. G. Freire, and U. Lins, Appl. Environ. Microbiol. 79,
2823 (2013).
53Y. Liu, G. R. Li, F. F. Guo, W. Jiang, Y. Li, and L. J. Li, Microb. Cell Fact. 9, 99
(2010).
54I. Ali, C. Peng, Z. M. Khan, and I. Naz, J. Basic Microbiol. 57, 643 (2017).
55E. Alphandéry, D. Abi Haidar, O. Seksek, F. Guyot, and I. Chebbi, Nanoscale
10, 10918 (2018).
56A. Plan Sangnier, S. Preveral, A. Curcio, A. K. A. Silva, C. T. Lefèvre,
D. Pignol, Y. Lalatonne, and C. Wilhelm, J. Controlled Release 279, 271 (2018).
57E. Alphandéry, Front Bioeng. Biotechnol. 2, 5 (2014).
58A. Muela, D. Muñoz, R. Martín-Rodríguez, I. Orue, E. Garaio, A. Abad Díaz
de Cerio, J. Alonso, J. Á. García, and M. L. Fdez-Gubieda, J. Phys. Chem. C 120,
24437 (2016).
59R. K. Gilchrist, R. Medal, W. D. Shorey, R. C. Hanselman, J. C. Parrott, and
C. B. Taylor, Ann. Surg. 146, 596 (1957).
60E. A. Périgo, G. Hemery, O. Sandre, D. Ortega, E. Garaio, F. Plazaola, and
F. J. Teran, Appl. Phys. Rev. 2, 041302 (2015).
61D. Ortega Ponce and Q. Pankhurst, in Nanoscience, edited by P. O’Brien
(Royal Society of Chemistry, 2012), pp. 60–88.
Journal of
Applied Physics PERSPECTIVE scitation.org/journal/jap
J. Appl. Phys. 128, 070902 (2020); doi: 10.1063/5.0018036 128, 070902-12
© Author(s) 2020
62Q. Pankhurst, S. Jones, and J. Dobson, J. Phys. D Appl. Phys. 49, 501002
(2016).
63Y. Zhang, W. Zhang, C. Geng, T. Lin, X. Wang, L. Zhao, and J. Tang, Prog.
Nat. Sci. 19, 1699 (2009).
64H. Gerad, D. A. Van Echo, M. Whitacre, M. Ashman, M. Helrich, J. Foy,
S. Ostrow, P. H. Wiernik, and J. Aisner, Cancer 53, 2585 (1984).
65R. Hergt, S. Dutz, R. Müller, and M. Zeisberger, J. Phys. Condens. Matter 18,
S2919 (2006).
66I. Andreu and E. Natividad, Int. J. Hyperthermia 29, 739 (2013).
67W. J. Atkinson, I. A. Brezovich, and D. P. Chakraborty, IEEE Trans. Biomed.
Eng. BME-31, 70 (1984).
68R. Hergt and S. Dutz, J. Magn. Magn. Mater. 311, 187 (2007).
69R. Das, J. Alonso, Z. Nemati Porshokouh, V. Kalappattil, D. Torres,
M.-H. Phan, E. Garaio, J. Á. García, J. L. Sanchez Llamazares, and H. Srikanth,
J. Phys. Chem. C 120, 10086 (2016).
70Z. Nemati, J. Alonso, I. Rodrigo, R. Das, E. Garaio, JÁ García, I. Orue,
M. H. Phan, and H. Srikanth, J. Phys. Chem. C 122, 2367 (2018).
71Z. Nemati, J. Alonso, L. M. Martinez, H. Khurshid, E. Garaio, J. A. Garcia,
M.-H. Phan, and H. Srikanth, J. Phys. Chem. C 120, 8370 (2016).
72D. Gandia, L. Gandarias, L. Marcano, I. Orue, D. Gil-Cartón, J. Alonso,
A. García-Arribas, A. Muela, and M. L. Fdez-Gubieda, Nanoscale 12, 16081 (2020).
73N. A. Usov and J. M. Barandiarán, J. Appl. Phys. 112, 053915 (2012).
74J. M. Byrne, V. S. Coker, S. Moise, P. L. Wincott, D. J. Vaughan, F. Tuna,
E. Arenholz, G. van der Laan, R. A. D. Pattrick, J. R. Lloyd, and N. D. Telling,
J. R. Soc. Interface 10, 20130134 (2013).
75N. A. Usov, J. Appl. Phys. 107, 123909 (2010).
76S. Laurent, S. Dutz, U. O. Häfeli, and M. Mahmoudi, Adv. Colloid Interface
Sci. 166, 8 (2011).
77C. Martinez-Boubeta, K. Simeonidis, A. Makridis, M. Angelakeris, O. Iglesias,
P. Guardia, A. Cabot, L. Yedra, S. Estradé, F. Peiró, Z. Saghi, P. A. Midgley,
I. Conde-Leborán, D. Serantes, and D. Baldomir, Sci. Rep. 3, 1652 (2013).
78M. Ma, Y. Wu, J. Zhou, Y. Sun, Y. Zhang, and N. Gu, J. Magn. Magn. Mater.
268, 33 (2004).
79J. Carrey, B. Mehdaoui, and M. Respaud, J. Appl. Phys. 109, 083921 (2011).
80N. A. Usov and S. E. Peschany, J. Magn. Magn. Mater. 174, 247 (1997).
81D. Gandia, L. Gandarias, I. Rodrigo, J. Robles-García, R. Das, E. Garaio, J.
Á. García, M. H. Phan, H. Srikanth, I. Orue, J. Alonso, A. Muela, and
M. L. Fdez-Gubieda, Small 15, 1902626 (2019).
82R. Le Fèvre, M. Durand-Dubief, I. Chebbi, C. Mandawala, F. Lagroix,
J. P. Valet, A. Idbaih, C. Adam, J. Y. Delattre, C. Schmitt, C. Maake, F. Guyot,
and E. Alphandéry, Theranostics 7, 4618 (2017).
83R. Liu, J. Liu, J. Tong, T. Tang, W.-C. Kong, X. Wang, Y. Li, and J. Tang, Prog.
Nat. Sci. Mater. Int. 22, 31 (2012).
84E. Alphandéry, I. Chebbi, F. Guyot, and M. Durand-Dubief, Int.
J. Hyperthermia 29, 801 (2013).
85E. Alphandéry, S. Faure, O. Seksek, F. Guyot, and I. Chebbi, ACS Nano 5,
6279 (2011).
86E. Alphandéry, A. Idbaih, C. Adam, J. Y. Delattre, C. Schmitt, F. Guyot, and
I. Chebbi, Biomaterials 141, 210 (2017).
87E. Alphandéry, A. Idbaih, C. Adam, J. Y. Delattre, C. Schmitt, F. Gazeau,
F. Guyot, and I. Chebbi, J. Nanobiotechnol. 17, 126 (2019).
88D. Chang, M. Lim, J. A. C. M. Goos, R. Qiao, Y. Y. Ng, F. M. Mansfeld,
M. Jackson, T. P. Davis, and M. Kavallaris, Front. Pharmacol. 9, 831 (2018).
89H. S. Huang and J. F. Hainfeld, Int. J. Nanomed. 8, 2521 (2013).
90A. J. Clark, D. T. Wiley, J. E. Zuckerman, P. Webster, J. Chao, J. Lin, Y. Yen,
and M. E. Davis, Proc. Natl. Acad. Sci. U.S.A 113, 3850 (2016).
91M. Molcan, H. Gojzewski, A. Skumiel, S. Dutz, J. Kovac, M. Kubovcikova,
P. Kopcansky, L. Vekas, and M. Timko, J. Phys. D Appl. Phys. 49, 365002 (2016).
92E. Alphandéry, S. Faure, L. Raison, E. Duguet, P. A. Howse, and
D. A. Bazylinski, J. Phys. Chem. C 115, 18 (2011).
93M. S. Tabatabaei, H. Girouard, and S. Martel, in International Conference on
Manipulation, Automation and Robotics at Small Scales, MARSS 2017—
Proceeding (Institute of Electrical and Electronics Engineers Inc., 2017), pp. 1–5.
94N. A. Usov and B. Y. Liubimov, J. Appl. Phys. 112, 023901 (2012).
95C. Chen, L. Chen, Y. Yi, C. Chen, L. F. Wu, and T. Song, Appl. Environ.
Microbiol. 82, 2219 (2016).
96J. Riegler, K. D. Lau, A. García-Prieto, A. N. Price, T. Richards,
Q. A. Pankhurst, and M. F. Lythgoe, Med. Phys. 38, 3932 (2011).
97M. R. Benoit, D. Mayer, Y. Barak, I. Y. Chen, W. Hu, Z. Cheng, S. X. Wang,
D. M. Spielman, S. S. Gambhir, and A. Matin, Clin. Cancer Res. 15, 5170 (2009).
98O. Felfoul, M. Mohammadi, S. Taherkhani, D. de Lanauze, Y. Zhong Xu,
D. Loghin, S. Essa, S. Jancik, D. Houle, M. Lafleur, L. Gaboury, M. Tabrizian,
N. Kaou, M. Atkin, T. Vuong, G. Batist, N. Beauchemin, D. Radzioch, and
S. Martel, Nat. Nanotechnol. 11, 941 (2016).
99S. Rismani Yazdi, R. Nosrati, C. A. Stevens, D. Vogel, P. L. Davies, and
C. Escobedo, Small 14, 1702982 (2018).
100I. S. M. Khalil, M. P. Pichel, B. A. Reefman, O. S. Sukas, L. Abelmann, and
S. Misra, in Proceedings—IEEE International Conference on Robotics and
Automation (IEEE, 2013), Vol. 5508.
101M. P. Pichel, T. A. G. Hageman, I. S. M. Khalil, A. Manz, and L. Abelmann,
J. Magn. Magn. Mater. 460, 340 (2018).
102P. E. Bunney, A. N. Zink, A. A. Holm, C. J. Billington, and C. M. Kotz,
Physiol. Behav. 176, 139 (2017).
103A. Codutti, K. Bente, D. Faivre, and S. Klumpp, PLoS Comput. Biol. 15,
e1007548 (2019).
104C. J. Pierce, E. Mumper, E. E. Brown, J. T. Brangham, B. H. Lower,
S. K. Lower, F. Y. Yang, and R. Sooryakumar, Phys. Rev. E 95, 062612 (2017).
105N. Waisbord, C. T. Lefèvre, L. Bocquet, C. Ybert, and C. Cottin-Bizonne,
Phys. Rev. Fluids 1, 53203 (2016).
106C. J. Pierce, H. Wijesinghe, E. Mumper, B. H. Lower, S. K. Lower, and
R. Sooryakumar, Phys. Rev. Lett. 121, 188001 (2018).
107J. Yu, B. Wang, X. Du, Q. Wang, and L. Zhang, Nat. Commun. 9, 3260
(2018).
108S. Rismani Yazdi, R. Nosrati, C. A. Stevens, D. Vogel, and C. Escobedo,
Biomicrofluidics 12, 011101 (2018).
109S. Klumpp, B. Kiani, P. Vach, and D. Faivre, Phys. Scr. T165, 014044
(2015).
110I. Kolinko, A. Lohße, S. Borg, O. Raschdorf, C. Jogler, Q. Tu, M. Pósfai,
E. Tompa, J. M. Plitzko, A. Brachmann, G. Wanner, R. Müller, Y. Zhang, and
D. Schüler, Nat. Nanotechnol. 9, 193 (2014).
111T. Prozorov, T. Perez-Gonzalez, C. Valverde-Tercedor, C. Jimenez-Lopez,
A. Yebra-Rodriguez, A. Körnig, D. Faivre, S. K. Mallapragada, P. A. Howse,
D. A. Bazylinski, R. Prozorov, “Manganese incorporation into the magnetosome
magnetite: Magnetic signature of doping,” Eur. J. Mineral. 26(4), 457–471
(2014).
112E. Alphandéry, C. Carvallo, N. Menguy, and I. Chebbi, J. Phys. Chem. C 115,
11920 (2011).
113L. Marcano, D. Munoz, R. Martín-Rodríguez, I. Orue, J. Alonso, A. García-Prieto,
A. Serrano, S. Valencia, R. Abrudan, L. Fernández Barquín, A. García-Arribas,
A. Muela, and M. L. Fdez-Gubieda, J. Phys. Chem. C 122, 7541 (2018).
114S. Staniland, W. Williams, N. Telling, G. Van Der Laan, A. Harrison, and
B. Ward, Nat. Nanotechnol. 3, 158 (2008).
115M. Tanaka, R. Brown, N. Hondow, A. Arakaki, T. Matsunaga, and
S. Staniland, J. Mater. Chem. 22, 11919 (2012).
116J. Li, N. Menguy, M. A. Arrio, P. Sainctavit, A. Juhin, Y. Wang, H. Chen,
O. Bunau, E. Otero, P. Ohresser, and Y. Pan, J. R. Soc. Interface 13, 20160355
(2016).
117A. Lohße, I. Kolinko, O. Raschdorf, R. Uebe, S. Borg, A. Brachmann,
J. M. Plitzko, R. Müller, Y. Zhang, and D. Schüler, Appl. Environ. Microbiol. 82,
3032 (2016).
118M. Luo, Y. Feng, T. Wang, and J. Guan, Adv. Funct. Mater. 28, 1706100 (2018).
119D. De Lanauze, O. Felfoul, J. P. Turcot, M. Mohammadi, and S. Martel, Int.
J. Rob. Res. 33, 359 (2014).
120N. Mokrani, O. Felfoul, F. Fatemeh Afkhami, M. Mohammadi, R. Aloyz,
G. Batist, and S. Martel, in 32nd Annual International Conference on IEEE
EMBS (IEEE, 2010), pp. 4371–4374.
Journal of
Applied Physics PERSPECTIVE scitation.org/journal/jap
J. Appl. Phys. 128, 070902 (2020); doi: 10.1063/5.0018036 128, 070902-13
© Author(s) 2020
121D. Jaque, L. Martínez Maestro, B. del Rosal, P. Haro-Gonzalez, A. Benayas,
J. L. Plaza, E. Martín Rodríguez, and J. García Solé, Nanoscale 6, 9494 (2014).
122M. Chu, Y. Shao, J. Peng, X. Dai, H. Li, Q. Wu, and D. Shi, Biomaterials 34,
4078 (2013).
123S. Mériaux, M. Boucher, B. Marty, Y. Lalatonne, S. Prévéral, L. Motte,
C. T. Lefèvre, F. Geffroy, F. Lethimonnier, M. Péan, D. Garcia,
G. Adryanczyk-Perrier, D. Pignol, and N. Ginet, Adv. Healthcare Mater. 4,
1076 (2015).
124Z. Xiang, X. Yang, J. Xu, W. Lai, Z. Wang, Z. Hu, J. Tian, L. Geng, and
Q. Fang, Biomaterials 115, 53 (2017).
125M. Boucher, F. Geffroy, S. Prévéral, L. Bellanger, E. Selingue,
G. Adryanczyk-Perrier, M. Péan, C. T. Lefèvre, D. Pignol, N. Ginet, and
S. Mériaux, Biomaterials 121, 167 (2017).
126J. H. Jung, Y. Tada, and P. C. Yang, in Biological, Physical and Techical Basics
of Cell Engineering, edited by G. M. Artmann, A. Artmann, A. A. Zhubanova,
and I. Digel (Springer, Singapore, 2018), pp. 365–380.
127M. Mahmoudi, A. Tachibana, A. B. Goldstone, Y. J. Woo, P. Chakraborty,
K. R. Lee, C. S. Foote, S. Piecewicz, J. C. Barrozo, A. Wakeel, B. W. Rice,
C. B. Bell, and P. C. Yang, Sci. Rep. 6, 1 (2016).
128B. Gleich and J. Weizenecker, Nature 435, 1214 (2005).
129X. L. C. Wu, X. Y. Zhang, X. G. Steinberg, X. H. Qu, X. S. Huang,
X. M. Cheng, X. T. Bliss, X. F. Du, X. J. Rao, X. G. Song, X. L. Pisani,
X. T. Doyle, X. S. Conolly, X. K. Krishnan, X. G. Grant, and X. M. Wintermark,
Am. J. Neuroradiol. 40, 206 (2019).
130A. Kraupner, D. Eberbeck, D. Heinke, R. Uebe, D. Schüler, and A. Briel,
Nanoscale 9, 5788 (2017).
Journal of
Applied Physics PERSPECTIVE scitation.org/journal/jap
J. Appl. Phys. 128, 070902 (2020); doi: 10.1063/5.0018036 128, 070902-14
© Author(s) 2020
